Based on the therapeutic responses we achieved with IRF5/IKKβ NPs administered directly into the peritoneal cavity to treat tumor lesions spread throughout the peritoneum, we next asked whether intravenously infused mRNA nanocarriers could program macrophages systemically to control disseminated disease. This evidence concerns the gene IRF5 and neoplasm.